PAREXEL International Corporation, the world’s leading innovator of biopharmaceutical services, launched its Biological Sample Lifecycle Management service, enabling optimal use of human biological samples.
The new service enables biopharmaceutical clients to more efficiently manage their often irreplaceable patient biological sample assets from informed consent and collection at site, through in-study laboratory analysis, data generation and future use. The offering combines PAREXEL’s laboratory logistics and genomic medicine expertise with BioFortis consent and sample tracking software.
Human biological samples are essential to global drug development, particularly in areas such as personalized, precision and genomic medicine. PAREXEL’s new offering helps clients maintain sample integrity, security and compliance with changing regulations and guidelines. In addition, the service provides advanced oversight of samples across the complex ecosystem of laboratories, biorepositories and research and development facilities.
“Today, biopharmaceutical companies are experiencing an increased demand to provide full visibility into the chain of custody and consent status of human samples throughout the entire lifecycle, which involves complex logistics and data flows,” said Sanjay Vyas, Corporate Vice President and Global Head, Clinical Trial Supplies and Logistics, PAREXEL. “With this new offering, PAREXEL is leveraging its wide range of expertise to help clients optimize sample management to meet this demand and ultimately accelerate clinical development cycles so new medicines can reach patients sooner.”
The Biological Sample Lifecycle Management offering combines PAREXEL’s services with BioFortis’ Labmatrix™ software, a technology-enabled solution for clinical trial sample and consent tracking allowing study teams to monitor samples across a complex study ecosystem.